NSABP B-55/BIG 6-13
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Reminder!
ENROLLMENT NOTICE: SYSTEM MAINTENANCE

Users will not be able to enroll to protocol NSABP-B-55 on Monday, January 23, 2017,
between 1:00 PM and 3:00 PM U.S. Eastern Time, due to system maintenance.

For assistance, call Randomization Support at 716-834-0900 ext. 7301.
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Unsubscribe